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Abstract. Chronic kidney disease (CKD) is an important 
cause of morbidity and mortality in HIV-infected individuals, 
even in the antiretroviral therapy (ART) era. Inflammatory 
cytokines and adipokines have been suggested to play a role 
in the development of CKD. The aim of the present study was 
to examine the circulating levels of a novel proinflammatory 
cytokine, angiopoietin-like protein 2 (ANGPTL2), in a cohort 
of 72 HIV-positive subjects on ART. HIV-positive patients 
were on cART for at least one year. Urine and blood samples 
were collected. Various factors were analyzed including 
body mass index (BMI), smoking, and presence/treatment 
for comorbidities such as diabetes. The estimated glomerular 
filtration rate was calculated by using the Chronic Kidney 
Disease Epidemiology Collaboration (CKD-EPI) equation. 
Plasma samples obtained were stored and used to measure 
sCD14 and ANGPTL2 levels. Data were presented as mean 
(± standard deviation) or median (interquartile range) for 
continuous variables. Categorical variables were expressed as 
number (%). Variables were compared using Student's t-test, 
Mann-Whitney test, or χ2 test. The results showed an inde-
pendent negative association between plasma ANGPTL2 and 
CKD-EPI values. Further prospective studies on larger cohorts 
are needed to evaluate the pathogenetic role of ANGPTL2 
as well as its use as a diagnostic marker of renal dysfunction.
Introduction
Chronic kidney disease (CKD) is a public health problem, and 
a major risk factor for end-stage kidney disease, cardiovascular 
disease and premature death. In HIV-infected subjects, CKD is 
the fourth cause of death for non-AIDS-related diseases, after 
malignancies, cardiovascular and liver disease (1-20). With 
the prolonged survival of HIV-infected individuals, the preva-
lence of CKD is expected to increase along with the burden of 
comorbidities, such as diabetes and hypertension (21).
In recent years, it has been suggested that inflamma-
tory cytokines play a role in the pathogenesis of CKD (22). 
Angiopoietin-like protein 2 (ANGPTL2) is an adipo-
kine belonging to the recently characterized family of 
ANGPTLs (23). Although structurally similar to angiopoietin, 
ANGPTLs do not bind to the classical angiopoietin receptors, 
and several members of the family are involved, not only in 
the regulation of angiogenesis, but also in glucose and lipid 
metabolism (23). ANGPTL2 is abundantly produced in fat 
tissue and its levels are increased in the setting of insulin 
resistance, obesity, and diabetes (23,24). Excess ANGPTL2 
secretion leads to chronic inflammation and endothelial 
dysfunction. Interestingly, in a recent report of Usui et al 
elevated circulating levels of ANGPTL2 were associated with 
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the likelihood of CKD in a large Japanese cohort of uninfected 
individuals (25). To date, however, no studies have investigated 
the link between serum ANGPTL2 levels and renal function 
in HIV-positive individuals.
The aim of the present study was to assess the relationship 
between circulating ANGPTL2 levels and renal function in a 
cohort of HIV-positive subjects on combination antiretroviral 
therapy (cART).
Subjects and methods
Study population. In this cross-sectional study, we consecu-
tively enrolled 72 HIV-positive patients attending the HIV 
Outpatient Clinic of the Division of Infectious Diseases in 
Catania, Italy, who were on cART for at least one year. All the 
participants provided written informed consent to participate 
in the study, which was conducted in accordance with the 
Declaration of Helsinki.
We extracted the following parameters from medical 
records: patient demographics, time since HIV diagnosis and 
initiation of cART, type of cART, HCV and/or HBV coinfec-
tion, body mass index (BMI), smoking, and presence/treatment 
for comorbidities, such as diabetes mellitus, hypertension, 
and dyslipidemia. At the time of enrollment, urine and blood 
samples were collected to evaluate CD4+ and CD8+ T cell 
count, plasma HIV RNA, highly sensitive (hs)-C reactive 
protein (CRP), presence of proteinuria and microalbuminuria. 
Estimated glomerular filtration rate (eGFR) was calcu-
lated by using the Chronic Kidney Disease Epidemiology 
Collaboration (CKD-EPI) equation. Plasma samples were 
stored at ‑80˚C and then used to measure sCD14 (Quantikine 
sCD14 Immunoassay; R&D Systems, Inc., Minneapolis, MN, 
USA) with a detection range of 40-3,200 ng/ml and ANGPTL2 
(Uscn Life Science Inc., Wuhan, China) with a detection range 
of 0.313-20 ng/ml levels, according to manufacturer's protocol.
Statistical analysis. Data were analyzed using the Statistical 
Package for Social Sciences version 22.0 (SPSS, Inc., Chicago, 
IL, USA). Data are presented as mean ± standard deviation 
for continuous variables with normal distribution or median 
(interquartile range) for continuous variables with skewed 
distribution. Categorical variables are expressed as number 
(%). Variables that were normally distributed, continuous but 
not normally distributed, or categorical were compared using 
Student's t-test, Mann-Whitney test, or χ2 test, respectively. 
Pearson's correlation test was used to assess the correlation 
of CKD-EPI values and demographic, biochemical and 
viro-immunological variables. Statistically significant 
variables in the univariate analysis (P<0.1) were included in the 
multivariate regression analysis, the dependent variable being 
CKD-EPI. In the multivariate regression model, both sCD14 
and ANGPTL2 were log-transformed (ln) to approximate 
normality. Presence of multicollinearity was checked by 
examining the variance inflation factor (VIF) and variables 
included in the final model if VIF was <5.
Results
Subject characteristics. The main demographic and clinical 
characteristics of the study population are reported in Table I. 
In total, 72 patients were enrolled, and all were Caucasian, with 
a median age of 47 (range, 36-53) years. As for risk factors for 
HIV acquisition, 26 individuals (36.1%) were heterosexual, 
and 40 (55.6%) were men having sex with men. In addition, 
14 (19.4%) women were included in the study. Median time 
since HIV diagnosis was 122 (range, 59-200) months, and 
median time since cART initiation was 72 (31-191) months. 
Median current CD4+ T cell count was 605 (409-789) cells/µl, 
while HIV viral load was <50 copies/ml in 59 patients (82%). Of 
the 72 patients, 27 patients (37.5%) received a protease inhibitor 
(PI)-based regimen, 57 (79.2%) were on tenofovir (TDF), and 
10 (13.9%) on raltegravir. In addition, 26 (36.1%) were smokers, 
and 6 patients (8.3%) were co-infected with hepatitis C. In terms 
of comorbidities, 34 subjects (47.2%) had a BMI >25 kg/m2, 
6.9% of the study population had diabetes, 18.1% hypertension, 
30.5% dyslipidemia. A total of 10 individuals (13.9%) had a 
high cardiovascular risk (i.e., Framingham risk score >20%), 
and 13.9% were taking lipid-lowering drugs.
Table I. Demographics and clinical characteristics of the study 
population.
Variable No. (n=72)
Age (years) 47 (36-53)
Sex, female [n (%)] 14 (19.4)
MSM [n (%)] 40 (56)
Time since HIV diagnosis (months) 122 (59-200)
Current CD4+ T-cell count (cells/µl) 605 (409-789)
HIV viral load <50 copies/ml [n (%)] 59 (82)
Time on cART (months) 72 (31-191)
Current use of PI [n (%)] 27 (37.5)
Current use of TDF [n (%)] 57 (79.2)
Current use of raltegravir [n (%)] 10 (13.9)
BMI (kg/m2) 24 (22-26.6)
Current smoking [n (%)] 26 (36.1)
Hepatitis C coinfection [n (%)] 6 (8.3)
Diabetes mellitus [n (%)] 5 (6.9)
Hypertension [n (%)] 13 (18.1)
Dyslipidemia [n (%)] 22 (30.6)
Framingham risk score (%) 4.5 (1-11.2)
eGFR (ml/min/1.73 m2),  96.9±18.5
based on CKD-EPI formula
Proteinuria [n (%)] 23 (32)
Microalbuminuria [n (%)] 18 (25)
hs-CRP (ng/ml) 0.18 (0.07-0.47)
ANGPTL2 (ng/ml) 2.09 (1.45-3.03)
sCD14 (ng/ml) 1,969 (1,747-2,292)
Data are mean ± standard deviation or median (interquartile range), 
unless otherwise specified. ANGPTL2, angiopoietin‑like protein 2; 
BMI, body mass index; cART, combination antiretroviral therapy; 
CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; 
eGFR, estimated glomerular filtration rate; HIV, human immunodefi-
ciency virus; hs-CRP, highly sensitive-C reactive protein; MSM, men 
having sex with men; PI, protease inhibitor; sCD14, soluble CD14; 
TDF, tenofovir.
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Renal function and predictors of reduced CKD‑EPI. Mean 
CKD-EPI was 96.9±18.5 ml/min; 25 patients (34.7%) had 
CKD-EPI <90 ml/min, while 2.8% had values <60 ml/min. In 
addition, 23 individuals (32%) had proteinuria, while 18 (25%) 
had microalbuminuria.
Individuals with high cardiovascular risk had decreased 
renal function compared to low-risk subjects (85 vs. 99 ml/min, 
P=0.03). As expected, patients on treatment for hypertension 
had lower CKD-EPI values (87 vs. 99 ml/min, P=0.07); 
similarly, individuals taking lipid-lowering drugs had lower 
CKD-EPI values when compared to those without dyslipid-
emia (86 vs. 98 ml/min, P=0.06).
All individuals had detectable levels of ANGPTL2. 
Median ANGPTL2 circulating level was 2.09 (1.45-3.03) 
ng/ml. Median sCD14 levels was 1,969 (1,747-2,292) ng/ml. 
Interestingly, we found that patients with ANGPTL2 values 
in the highest tertile (i.e., ANGPTL2 values ≥2.62 ng/ml) 
had significantly lower CKD‑EPI values when compared to 
the rest of the cohort (86 vs. 103 ml/min, P=0.001) (Fig. 1A). 
Analogously, individuals with sCD14 values in the upper 
tertile (i.e., sCD14 values ≥2,072 ng/ml) had lower CKD-EPI 
values (89 vs. 101 ml/min, P=0.02) (data not shown).
As expected, CKD-EPI values were negatively correlated 
with age (r=-0.56, P<0.001). Moreover, they were negatively 
correlated with Framingham risk score (r=-0.37, P=0.001), 
sCD14 levels (r=-0.37, P=0.002) and ANGPTL2 (r=-0.47, 
P<0.001; Fig. 1B).
In multivariate analysis, only older age (β=-0.42, P=0.013) 
and higher circulating ANGPTL2 (β=-0.29, P=0.024) 
remained significantly associated with reduced CKD-EPI 
values (Table II).
Discussion
In the present study, we found an independent associa-
tion between reduced renal function and elevated levels of 
ANGPTL2 in a cohort of HIV-positive individuals on cART. 
ANGPTL2 is a recently characterized adipokine, which has 
been associated with several metabolic disorders, including 
insulin resistance, obesity and diabetes (23,24). Existing 
studies have shown that ANGPTL2 can act as a mediator of 
chronic inflammation (23). ANGPTL2 is mainly produced 
in visceral adipose tissue, where it promotes macrophage 
recruitment and neoangiogenesis. In obese mice, elevated 
levels of ANGPTL2 led to chronic adipose tissue inflam-
mation and remodeling, and finally to systemic insulin 
resistance (24). Similarly, in obese humans, elevated levels of 
ANGPTL2 have been associated with the presence of insulin 
resistance as well as the risk of developing diabetes (24,26). 
Moreover, both in animal and human studies, elevated 
ANGPTL2 levels have been positively correlated with 
vascular inflammation and atherosclerosis progression (24). 
Inflammatory cytokines and adipokines, such as resistin, 
visfatin and adiponectin, have been suggested to play a role 
Table II. Multivariate regression model for CKD-EPI, including factors associated with reduced renal function in univariate 
analysis.
Variables β B (SE) P-value
Age (per year) -0.42 -0.67 (0.26) 0.013
ANGPTL2 (ln, ng/ml) -0.29 -7.7 (3.3) 0.024
sCD14 (ln, ng/ml)  -0.19 -21.9 (12.9) 0.095
Framingham risk score (%) 0.15  0.31 (0.29) 0.29
Antihypertensive therapy, yes -0.03 -1.1 (5.3) 0.83
Lipid-lowering drugs, yes 0.002 0.11 (5.9) 0.98
ANGPTL2, angiopoietin-like protein 2; β, standardized coefficient; B, unstandardized coefficient; sCD14, soluble CD14; SE, standard error.
Figure 1. (A) Distribution of Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) values according to circulating angiopoietin-like protein 2 
(ANGPTL2) levels. CKD‑EPI values were significantly lower in individuals with ANGPTL2 ≥2.62 ng/ml, corresponding to the upper tertile of ANGPTL2 
distribution (86 vs. 103 ml/min, P=0.001). (B) Correlation between CKD-EPI and ANGPTL2 circulating levels in the study population (r=-0.47, P<0.001).
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in the development of CKD. In a large population-based 
study recently conducted in Japan, the authors found that 
circulating ANGPTL2 levels were independently associ-
ated with the likelihood of CKD (25). In this study, CKD 
was defined as the presence of albuminuria or eGFR 
<60 ml/min. The authors reported that the odds ratio (OR) 
for CKD increased with elevated circulating ANGPTL2. 
The OR for CKD was analyzed across quintiles and found 
to be significantly higher in the second quintile [ANGPTL2 
values 2.01-2.48 ng/ml, OR=1.67, 95% confidence interval 
(CI): 1.24‑2.24], and thereafter to plateau to the fifth quintile 
(OR=1.79, 95% CI: 1.32-2.43). The association remained 
significant after correcting for known cardiovascular risk 
factors and hs-CRP levels. However, when separating eGFR 
and albuminuria as markers of reduced renal function, only 
the latter remained significantly associated with circulating 
ANGPTL2 levels. In our study, the limited sample size did 
not allow us to evaluate whether ANGPTL2 was a predictor 
of albuminuria or not. By immunochemistry, ANGPT2 has 
been shown to be upregulated in the glomeruli of subjects 
with diabetes (25). Moreover, ANGPTL2 has been reported 
to activate the NF-κB pathway in endothelial cells. As 
NF-κB upregulation in the glomerulus has been correlated 
with albuminuria, it can be hypothesized that increased 
ANGPTL2 levels may represent a marker of endothelial 
dysfunction and chronic inflammation in multiple organs, 
including the kidney (24,27,28).
The presence of abnormalities in renal function is frequent 
in HIV-positive individuals (21). Up to 30% of HIV-positive 
individuals have proteinuria and 4% of them can develop 
CKD over time. In addition to traditional risk factors, such 
as aging, diabetes, chronic hepatitis, hypertension, and black 
ethnicity, several HIV-related factors can increase the risk of 
CKD, including low CD4+ T cell nadir, elevated HIV viral 
load, and exposure to some antiretroviral drugs, especially 
TDF and PIs (21). HIV-positive individuals are known to have 
increased levels of chronic inflammation and immune activa-
tion compared to the general population (29). We hypothesize 
therefore that elevated levels of ANGPTL2 may reflect this 
proinflammatory status. Although the design of the study is 
not appropriate to assess causality, ANGPTL2 may be a multi-
organ marker of endothelial dysfunction and, more specifically, 
a marker of renal impairment in this case. With the increase 
in life expectancy and comorbidities in HIV-infected indi-
viduals, identification of a novel marker of renal dysfunction 
can help design more effective strategies to prevent or delay 
the progression towards CKD.
Our study has several limitations: first, the small sample 
size, which limits the statistical power of our analysis; 
second, the lack of a control group of uninfected individuals; 
third, its cross-sectional design, which does not allow to 
establish causal relationships. In fact, we cannot exclude that 
increased ANGPTL2 results from reduced renal function, 
although ANGPTL2 should not be filtered by the glom-
erulus, considering its molecular weight of 57 kDa (25). 
On the basis of our findings, we are currently enrolling a 
larger cohort of individuals on cART and a matched group 
of HIV-negative subjects in order to validate the results of 
this pilot study. Moreover, we are currently interested in 
evaluating ANGPTL2 levels in untreated HIV infection and 
establishing whether circulating ANGPTL2 levels change 
over time after starting cART.
In conclusion, to the best of our knowledge, this is the first 
study to identify an association between renal dysfunction and 
increased circulating ANGPTL2. Further research is needed 
to clarify the potential pathogenetic mechanisms underlying 
this association as well as assess whether ANGPTL2 may 
represent a novel marker of declining renal function in HIV 
infection.
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